Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study

Journal of Human Hypertension volume 18, pages 669–675 (2004)Cite this article

Abstract

Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism. We assessed the efficacy of moxonidine in a postmarketing surveillance study (CAMUS) conducted in 772 practices in Germany, documenting 4005 patients with hypertension, who were overweight and/or suffered from metabolic syndrome. Patients were treated with moxonidine (Cynt®) for the first time following the baseline visit for 8 weeks. Mean blood pressure decreased from 168/97 to 141/83 mmHg for all patients and from 168/96 to 141/83 mmHg for patients with metabolic syndrome. Blood pressure reduction was particularly pronounced in patients with severe hypertension at baseline. The response rate (DBP⩽90 mmHg or reduction ⩾10 mmHg) of antihypertensive treatment with moxonidine was 94.0% for all patients and 93.8% for patients with metabolic syndrome. The recommended targets for antihypertensive treatment of the German Diabetes Society/German Hypertension Society were reached by 30.5% of nondiabetics (goal: <140/90 mmHg) and by 3.6% of diabetics (goal: <130/80 mmHg) observed. After 8 weeks of treatment, patients achieved a mean weight loss of 1.4 kg, which was particularly pronounced in obese patients. The rate of patients receiving antihypertensive combination therapy was 81.1% for those with metabolic syndrome, and 63.3% for all other patients. Patients with metabolic syndrome were preferentially treated with ACE inhibitors and diuretics. We conclude that moxonidine effectively reduces blood pressure in patients with metabolic syndrome while simultaneously reducing body weight in obese patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Camus JP . Goutte, diabete, hyperlipemie. Un trisyndrome metabolique. Revue du Rhumatisme 1966; 33: 10–14.

    CAS  Google Scholar 

  2. Jahnke K et al. Hormonal and metabolic aspects of obesity in humans. In: Östmann J (ed.). Diabetes. Proceedings of the 6th Congress of the International Diabetes Federation. Excerpta Medica Foundation: Amsterdam, 1969, pp. 533–539.

    Google Scholar 

  3. Mehnert H, Kuhlmann H . Hypertonie und Diabetes mellitus. Dtsch Med J 1968; 19: 567–571.

    CAS  PubMed  Google Scholar 

  4. Reaven GM . Banting lecture 1998. Role of insulin resistance in human diseases. Diabetes 1969; 37: 1595–1607.

    Article  Google Scholar 

  5. Alberti KG, Zimmet PC . Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539–553.

    Article  CAS  PubMed  Google Scholar 

  6. Burt VL et al. Prevalence of hypertension in the US adult population. Results from the third national health and nutrition examination survey, 1988–1991. Hypertension 1995; 25: 305–313.

    Article  CAS  PubMed  Google Scholar 

  7. Grossman E, Messerli FH . Diabetic and hypertensive heart disease. Ann Intern Med 1996; 125: 304–310.

    Article  CAS  PubMed  Google Scholar 

  8. Lakka H-M et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716.

    Article  PubMed  Google Scholar 

  9. Laaksonen DE et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 158: 1070–1077.

    Article  Google Scholar 

  10. Borch-Johnson K et al. Blood pressure after 40 years of insulin-dependent diabetes. Nephron 1995; 4: 11–12.

    Article  Google Scholar 

  11. Hansson L, Zanchetti A, Carruthers SG . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principle results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998; 351: 1755–1762.

    Article  CAS  PubMed  Google Scholar 

  12. UKPDS group. Tight blood pressure control an risk of macrovascular and microvascular complication in type 2 diabetes: UKPDS38. BMJ 1998; 317: 703–713.

    Article  PubMed Central  Google Scholar 

  13. WHO/ISH. Guidelines for the management of hypertension. J Hypertens 1999; 17: 151–183.

  14. Hochdruckliga. Leitlinie für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie. Dtsch Med Wochenschr 2001; 126 (Suppl. 4): 201–238.

  15. ALLHAT officers. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981–2997.

  16. Ehrnsberger P . Pharmacology of moxonidine: An I1-imidazoline receptor antagonist. J Cardiovasc Pharmacol 2000; 35: S27–S41.

    Article  Google Scholar 

  17. Prichard BN et al. A double blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1992; 20: S45–S49.

    Article  Google Scholar 

  18. Schäfers R et al. Wirksamkeit und Verträglichkeit des neuen zentralwirsamen Antihypertensivums Moxonidin im Vergleich zu Enalapril. Nieren und Hochdruckkrankheiten 1994; 5: S221–S224.

    Google Scholar 

  19. Waters J et al. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertenion—results of the TOPIC study. J Clin Basic Cardiol 1999; 2: 219.

    CAS  Google Scholar 

  20. Wolf R . The treatment of hypertensive patients with a calcium antagonist or moxonidine: A comparison. J Cardiovasc Pharmacol 1992; 20: S42–44.

    Article  Google Scholar 

  21. Chrisp P, Faulds D . Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension. Drugs 1992; 44: 993–1012.

    Article  CAS  PubMed  Google Scholar 

  22. Haenni A, Lithell H . Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 1999; 17 (Suppl. 3): 29–35.

    Google Scholar 

  23. Kaan EC et al. Effects of agmantine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risc Factors 1995; 5 (Suppl. 1): 19–27.

    Google Scholar 

  24. Marsalek P, Helsberg K, Motz W . Hypertoniebehandlung mit Moxonidin: Anwendungsbeobachtung dokumentiert Wirkung, Verträglichkeit und ärztliches Therapieverhalten. Perfusion 2002; 15: 191–200.

    Google Scholar 

  25. Prichard BN et al. Moxonidine: a new antiadrenergic antihypertensive agent. J Hypertens 1999; 17 (Suppl. 3): S41–S54.

    CAS  Google Scholar 

  26. Prichard BN et al. The use of moxonidine in the treatment of hypertension. J Hypertens 1999; 15 (Suppl. 11): 1366.

    Google Scholar 

  27. Vonend O et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21: 1709–1717.

    Article  CAS  PubMed  Google Scholar 

  28. Fagard RH et al. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens 2002; 20: 1297–1302.

    Article  CAS  PubMed  Google Scholar 

  29. National Institute of Health. Diagnosis and Management of Hypertension—1987. A Nationwide Survey of Physicians’ Knowledge, Attitude, and Reported Behavior. NIH Publication: Bethesda, MD, 1989, pp. 89–2968.

  30. Hagemeister J et al. Hypertension guidelines and their limitations—the impact of physicians compliance as evaluated by guidelines awareness. J Hypertens 2001; 19: 2079–2086.

    Article  CAS  PubMed  Google Scholar 

  31. Aparina TV et al. ACE-dependent and sympathetic components of blood pressure regulation in patients with essential hypertension. Vopr Med Khim 2001; 47: 411–418.

    CAS  PubMed  Google Scholar 

  32. Lithell HO . Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent. J Hypertens 1997; 15: S39–S42.

    Article  CAS  Google Scholar 

  33. Sanjuliani AF et al. Moxonidine and amlodipine effects on lipid profile, urinary sodium excretion and caloric intake in obese hypertensive patients. Am J Hypertens 2000; 13: 144A.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. McMaster University, Hamilton, ON, Canada

    A M Sharma

  2. Lilly Deutschland GmbH, Bad Homburg, Germany

    T Wagner & P Marsalek

Authors
  1. A M Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Marsalek
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharma, A., Wagner, T. & Marsalek, P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens 18, 669–675 (2004). https://doi.org/10.1038/sj.jhh.1001676

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001676

Keywords

This article is cited by

Search

Advanced search

Quick links